Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Obesity
Clinical trial register · Poland

Obesity Trials in Poland, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2709 matching records held by the registry are in this view. Synced 12 Nov 2026, 03:19 UTC
2709
Studies in scope
all four open statuses
1380
Recruiting now
open to new participants
510
Lead sponsors
across recruiting studies
Top sites
Bialystok 24 Warsaw 23 Krakow 19 Lodz 14 Lublin 13
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Novo Nordisk A/S14 Eli Lilly and Company10 Amgen4 Medical University of Bialystok4 Pfizer2 Kailera2 Ascletis Pharma (China) Co., Limited2 Miedziowe Centrum Zdrowia SA1 Hoffmann-La Roche1 Medical University of Warsaw1 Jan Kochanowski University1 KeyBioscience AG1
Site location
Bialystok24 Warsaw23 Krakow19 Lodz14 Lublin13 Bydgoszcz13 Gdansk12 Poznan11 Wroclaw10 Katowice10 Gdynia9 Zabrze5 Elblag5 Rzeszów5 Częstochowa4 Ruda Śląska3 Chrzanów3 Dębica3 Leszno2 Legnica2 Gorzów Wielkopolski2 Bielsko-Biala2 Chojnice2 Stanisławów Pierwszy2 Grodzisk Mazowiecki2 Show all 49
All 49 locations
Target enrolment
to

Obesity trials in Poland

43 of 2709 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Poland
Start
Not yet open
GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry
NCT07787936Heart Failure With Preserved Ejection Fraction, Obesity, Diastolic Heart Failure, Pulmonary Hypertension
Miedziowe Centrum Zdrowia SA
Observational
150
Lubin
2027-01-01
Not yet open
Eli Lilly and Company
Phase 3
3,000
Bialystok, Krakow, Lublin, Piotrkow Trybunalski
2026-12
Not yet open
Novo Nordisk A/S
Phase 3
1,408
Grodzisk Mazowiecki, Ostrów Mazowiecka, Warsaw, Gdynia, Elblag, Gdansk, Krakow, Lodz
2026-11-11
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Lublin, Gorzów Wielkopolski, Grodzisk Mazowiecki, Ostrów Mazowiecka, Warsaw, Bialystok, Częstochowa, Bielsko-Biala
2026-10-26
Recruiting
Eli Lilly and Company
Phase 3
150
Lodz, Rzeszów, Stanisławów Pierwszy, Warsaw, Warszewo, Wroclaw
2026-09-25
Recruiting
Ascletis Pharma (China) Co., Limited
Phase 3
3,003
Biała Podlaska, Bydgoszcz, Częstochowa, Gdansk, Gdynia, Katowice, Krakow, Lodz
2026-08-31
Recruiting
Ascletis Pharma (China) Co., Limited
Phase 3
1,560
Biała Podlaska, Bydgoszcz, Częstochowa, Gdansk, Gdynia, Katowice, Krakow, Lodz
2026-08-28
Recruiting
Novo Nordisk A/S
Phase 3
450
Bialystok, Bydgoszcz, Bygdoszcz, Lodz, Poznan, Staszów, Warsaw
2026-08-12
Recruiting
Pfizer
Phase 3
954
Bialystok, Gdansk, Lublin, Poznan, Wroclaw
2026-06-10
Recruiting
Genetic, Microbiological and Behavioral Factors in Obesity
NCT07650149Obesity & Overweight, Obesity, Genetics
Jan Kochanowski University
Observational
200
Krakow, Warsaw
2026-05-23
Recruiting
Novo Nordisk A/S
Phase 3
2,500
Bialystok, Bydgoszcz, Dębica, Katowice, Krakow, Poznan, Rzeszów, Warsaw
2026-05-21
Active, closed
Novo Nordisk A/S
Phase 3
985
Ruda Śląska, Leszno, Grudziądz, Lublin, Legnica, Gorzów Wielkopolski, Bialystok, Elblag
2026-05-20
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Leszno, Chrzanów, Tarnów, Lublin, Płock, Gdynia, Ustroń, Szczecin
2026-05-11
Recruiting
Novo Nordisk A/S
Phase 3
300
Wroclaw, Gdansk, Krakow, Poznan, Warsaw
2026-05-05
Recruiting
Novo Nordisk A/S
Phase 3
300
Wroclaw, Gdansk, Krakow, Poznan, Warsaw
2026-05-05
Recruiting
Novo Nordisk A/S
Phase 3
400
Bialystok, Bydgoszcz, Krakow, Warsaw
2026-04-20
Recruiting
Novo Nordisk A/S
Phase 3
400
Bialystok, Bydgoszcz, Krakow, Warsaw
2026-04-13
Active, closed
Pfizer
Phase 3
1,078
Lodz, Bialystok, Bydgoszcz, Chojnice, Częstochowa, Gdansk, Gdynia, Katowice
2026-02-24
Recruiting
Eli Lilly and Company
Phase 3
1,980
Bialystok, Krakow, Lodz, Lublin, Poznan, Wroclaw, Zabrze
2026-02-06
Recruiting
Novo Nordisk A/S
Phase 3
460
Dziekanów Leśny, Opole, Rzeszów, Zabrze
2026-01-08
Active, closed
Kailera
Phase 3
1,270
Krakow, Warsaw, Gdynia, Chorzów, Bydgoszcz, Wroclaw, Kielce
2025-12-30
Active, closed
Amgen
Phase 3
250
Bialystok, Poznan, Warsaw
2025-12-19
Active, closed
Kailera
Phase 3
2,530
Poznan, Torun, Krakow, Siedlce, Warsaw, Skierniewice, Zamość
2025-12-18
Recruiting
Eli Lilly and Company
Phase 3
1,035
Bialystok, Bydgoszcz, Elblag, Krakow, Lodz, Lublin, Ruda Śląska, Zabrze
2025-12-15
Active, closed
Novo Nordisk A/S
Phase 3
300
Bialystok, Katowice, Lublin, Warsaw
2025-11-05
Active, closed
Amgen
Phase 3
12,800
Bialystok, Bielsko-Biala, Bydgoszcz, Chojnice, Chrzanów, Dębica, Gdynia, Katowice
2025-07-25
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Bialystok, Bydgoszcz, Chrzanów, Elblag, Gdansk, Gdynia, Giżycko, Katowice
2025-06-25
Active, closed
Eli Lilly and Company
Phase 3
586
Bialystok
2025-05-29
Active, closed
Hoffmann-La Roche
Phase 2
285
Krakow, Gdansk, Lublin, Warsaw
2025-05-05
Active, closed
Amgen
Phase 3
3,853
Bialystok, Dębica, Gdynia, Katowice, Lodz, Lublin, Poznan, Warsaw
2025-03-12
Recruiting
Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis
NCT06833749Osteoarthritis in the Knee, Obesity
KeyBioscience AG
Phase 2
600
Bytom, Poznan, Swidnica, Warsaw, Wroclaw
2025-01-28
By invitation
Chronic Abdominal Pain After Laparoscopic Sleeve Gastrectomy
NCT06686875Obesity, Chronic Pain, Abdominal Pain
Medical University of Warsaw
Observational
200
Warsaw
2024-12-01
Recruiting
Eli Lilly and Company
Phase 3
125
Krakow, Lodz, Rzeszów, Stanisławów Pierwszy, Warsaw, Wroclaw
2024-11-18
Recruiting
Eli Lilly and Company
Phase 3
150
Krakow, Warsaw, Warszewo, Wroclaw
2024-11-18
Active, closed
Eli Lilly and Company
Phase 3
800
Poznan, Lublin, Bialystok, Ruda Śląska, Lodz
2024-11-01
Active, closed
Novo Nordisk A/S
Phase 4
500
Wroclaw, Gdansk, Katowice, Lodz, Rzeszów, Stanisławow Pierwszy Nieporet, Warsaw, Zabrze
2024-09-17
Active, closed
Eli Lilly and Company
Phase 3
160
Warsaw, Zabrze, Lodz
2023-10-16
Active, closed
Novo Nordisk A/S
Phase 3
3,400
Bydgoszcz, Krakow, Legnica, Lublin, Warsaw, Bialystok, Gdansk, Katowice
2022-11-01
Active, closed
Eli Lilly and Company
Phase 3
15,374
Bialystok, Bydgoszcz, Chorzów, Elblag, Gdansk, Krakow, Lodz, Lublin
2022-10-11
Recruiting
Genetics of the Acute Response to Oral Semaglutide
NCT05340868PreDiabetes, Prediabetic State, Obesity
DrugsSemaglutide Pill·Semaglutide
Medical University of Bialystok
Not applicable
1,000
Bialystok
2022-09-01
Recruiting
Polish Registry of Diabetes (PolReD)
NCT04657367Diabetes, Obesity, PreDiabetes, Dysglycemia
Medical University of Bialystok
Observational
10,000
Bialystok
2020-02-03
By invitation
Białystok PLUS - Polish Longitudinal University Study
NCT03197363Cardiovascular Diseases, Diabetes, Neuro-Degenerative Disease, Obesity
Medical University of Bialystok
Observational
8,320
Bialystok
2018-11-05
Recruiting
The Bialystok Bariatric Surgery Study
NCT04634591Obesity, Diabetes Mellitus, Metabolic Syndrome, Dyslipidemias
Medical University of Bialystok
Observational
1,000
Bialystok
2015-09-10
Rows per page Showing 1–43 of 43
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 November 2026. https://priyalifescience.com/clinical-trials-poland/condition/obesity

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,709 studies in total at the last sync on 12 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 43 of those studies listing the condition Obesity.

How many Obesity trials are recruiting in Poland?

22 of the 43 studies on this page are recruiting new participants as of the 12 Nov 2026, 03:19 UTC sync. A further 4 have not yet opened recruitment, 15 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Obesity), 43 studies
PhaseStudiesRecruitingShare
Phase 3331776.7%
Observational6314%
Phase 2214.7%
Not applicable112.3%
Phase 4102.3%

Most active sponsors

Lead sponsors with the most studies (Obesity)
Lead sponsorStudiesRecruiting
Novo Nordisk A/S148
Eli Lilly and Company105
Amgen41
Medical University of Bialystok43
Ascletis Pharma (China) Co., Limited22
Kailera20
Pfizer21
Hoffmann-La Roche10
Jan Kochanowski University11
KeyBioscience AG11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.